Hipertensión arterial pulmonar y deterioro renal en pacientes del Instituto Nacional de Cardiología Ignacio Chávez, México

Franklyn  Colón; Anthony  Gutiérrez; Annette G. García; Lorgis Jiménez; Diego E. Arbaje; Nayeli Zayas

doi:10.47487/apcyccv.v2i4.150

Authors

Franklyn Colon Departamento de Cardiologia, Clinica Corominas. Santiago de los Caballeros, Republica Dominicana. https://orcid.org/0000-0001-5366-0342
Anthony Gutierrez Departamento de Medicina, Facultad de Ciencias de la Salud Pontificia Universidad Catolica Madre y Maestra. Santiago de los Caballeros, Republica Dominicana. https://orcid.org/0000-0003-4567-0123
Annette G. Garcia Departamento de Medicina, Facultad de Ciencias de la Salud Pontificia Universidad Catolica Madre y Maestra. Santiago de los Caballeros, Republica Dominicana. https://orcid.org/0000-0002-2604-7275
Lorgis Jimenez Departamento de Medicina, Facultad de Ciencias de la Salud Pontificia Universidad Catolica Madre y Maestra. Santiago de los Caballeros, Republica Dominicana. https://orcid.org/0000-0001-6774-7860
Diego E. Arbaje Departamento de Medicina, Facultad de Ciencias de la Salud Pontificia Universidad Catolica Madre y Maestra. Santiago de los Caballeros, Republica Dominicana. https://orcid.org/0000-0002-4988-2310
Nayeli Zayas Departamento de Cardioneumologia, Instituto Nacional de Cardiologia Dr. Ignacio Chavez. Ciudad de Mexico, Mexico. https://orcid.org/0000-0002-0920-2448

DOI:

https://doi.org/10.47487/apcyccv.v2i4.150

Keywords:

Chronic kidney disease, Pulmonary arterial hypertension, Cardio-renal syndrome

Abstract

Objective. The objective of the study was to describe the clinical characteristics and the evolution of the severity of pulmonary arterial hypertension (PAH) and the degree of renal failure. Material and methods. A retrospective observational study was carried out in which the physical and electronic medical records of 60 patients older than 18 years with a diagnosis of pulmonary arterial hypertension were analyzed. Results. In our study, 11.4% of the severe PAH group worsened renal function at six months, and 13.6% of the participants worsened it at one year. In contrast, in the group with moderate PAH, 18.8% worsened at six months, and 12.5% worsened at one year. Also, the GFR at one year was 54.15 mL/min/1.73 m2 in the moderate PAH group and in the severe PAH group was 73.55 mL/min/1.73 m2. Conclusion. The results of this research suggest that the deterioration of kidney function is related to the severity of pulmonary arterial hypertension.

Downloads

Download data is not yet available.

References

Torres C. Insuficiencia renal crónica. Rev Med Hered. 2003;14(1):1-4.

Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1801913. doi: 10.1183/13993003.01913-2018.

Ordoñez-Vázquez AL, Montes-Castillo C, Mora-Soto JR, Sánchez-Hernández JD. Hipertensión arterial pulmonar. Residente. 2015;10(1):18-30.

Lorenzo V. Enfermedad renal crónica. En: Sociedad Española de Nefrología. Nefrología al día. Barcelona, España: Grupo editorial nefrología de La Sociedad Española de Nefrología; 2010. p. 335-352.

Pabst S, Hammerstingl C, Hundt F, Gerhardt T, Grohé C, Nickenig G, et al. Pulmonary hypertension in patients with chronic kidney disease on dialysis and without dialysis: results of the PEPPER-study. PLoS One. 2012;7(4):e35310. doi: 10.1371/journal.pone.0035310.

Sise ME, Courtwright AM, Channick RN. Pulmonary hypertension in patients with chronic and end-stage kidney disease. Kidney Int. 2013;84(4):682-92. doi: 10.1038/ki.2013.186.

Reque J, Garcia-Prieto A, Linares T, Vega A, Abad S, Panizo N, et al. Pulmonary Hypertension Is Associated with Mortality and Cardiovascular Events in Chronic Kidney Disease Patients. Am J Nephrol. 2017;45(2):107-14. doi: 10.1159/000453047.

Abernethy AD, Stackhouse K, Hart S, Devendra G, Bashore TM, Dweik R, Krasuski RA. Impact of diabetes in patients with pulmonary hypertension. Pulm Circ. 2015;5(1):117-23. doi: 10.1086/679705.

Agarwal R. Prevalence, determinants and prognosis of pulmonary hypertension among hemodialysis patients. Nephrol Dial Transplant.. 2012;27(10):3908-14. doi: doi.org/10.1093/ndt/gfr661.

Bolignano D, Rastelli S, Agarwal R, Fliser D, Massy Z, Ortiz A, et al. Pulmonary hypertension in CKD. Am J Kidney Dis. 2013;61(4):612-22. doi: 10.1053/j.ajkd.2012.07.029

Vonk-Noordegraaf A, Souza R. Cardiac magnetic resonance imaging: what can it add to our knowledge of the right ventricle in pulmonary arterial hypertension? Am J Cardiol. 2012;110(6 Suppl):25S-31S. doi: 10.1016/j.amjcard.2012.06.013.

Sharma M, Pinnamaneni S, Aronow WS, Jozwik B, Frishman WH. Existing drugs and agents under investigation for pulmonary arterial hypertension. Cardiol Rev. 2014;22(6):297-305. doi: 10.1097/CRD.0000000000000035.

Frantz RP, Farber HW, Badesch DB, Elliott CG, Frost AE, McGoon MD, et al. Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry. Chest. 2018;154(1):126-135. doi: 10.1016/j.chest.2018.01.009.

Brittain EL, Janz DR, Austin ED, Bastarache JA, Wheeler LA, Ware LB, et al. Elevation of plasma cell-free hemoglobin in pulmonary arterial hypertension. Chest. 2014;146(6):1478-1485. doi: 10.1378/chest.14-0809.

Navaneethan SD, Wehbe E, Heresi GA, Gaur V, Minai OA, Arrigain S, et al. Presence and outcomes of kidney disease in patients with pulmonary hypertension. Clin J Am Soc Nephrol. 2014;9(5):855-63. doi: 10.2215/CJN.10191013.